Abstract: Disclosed are water-based personal cleansing compositions having an isotropic surfactant phase, the compositions containing (a) cationic surfactant that includes a quaternary ammonium compound and/or an amidoamine, (b) cleansing surfactant and (c) water, the cleansing surfactant containing 85 to 100% by weight of a combination of betaine surfactant and taurate surfactant in particular ratios; also disclosed are methods of thickening such compositions by the addition of electrolyte.

Abstract: Hair care compositions and methods for improving curl retention of hair are provided. The hair car composition may include a carrier and a quaternary ammonium compound. The method for improving curl retention may include contacting the hair care composition with surfaces of the hair of a subject in need thereof.

Abstract: A hair cosmetic comprising the following components (A) and (B) at a mass ratio of component (B) to component (A), (B)/(A), of 0.7 or more and 5.0 or less: (A) an aromatic sulfonic acid having a molecular weight of 300 or less or a salt thereof; and (B) a cationic polymer having a cationic charge density of 4.5 meq/g or more.

Abstract: The invention relates to novel spiroketal antioxidants, including compounds of Formula (I) and (II). The compounds have antioxidant properties and are useful for the treatment and/or prevention of diseases and conditions associated with oxidative stress in the body (e.g., metabolic conditions, neurodegenerative diseases, cardiovascular diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, renal diseases). The invention provides pharmaceutical compositions comprising the compounds, and kits comprising the same. Additionally, the invention provides uses of the compounds described herein (e.g., for inhibiting the concentration or production of reactive oxygen species (ROS), inhibiting the concentration or production of reactive nitrogen species (RNS), reducing oxidative stress, inhibiting NADPH oxidase activity, and for slowing or reducing the effects of aging).

Abstract: Suggested is a method for improving skin whitening power of a skin whitening agent in a cosmetic or dietary supplement composition comprising or consisting of the following step: (a) providing a cosmetic composition comprising at least one skin whitening agent selected form the group consisting of kojic acid and phenylethyl resorcinol, beta- and alpha-arbutin, hydroquinone, nicotinamide, dioic acid, Mg ascorbyl phosphate and vitamin C and its derivatives, mulberry extract, Bengkoang extract, papaya extract, turmeric extract, nutgrass extract, licorice extract (containing glycyrrhizin), alpha-hydroxy-acids, 4-alkylresorcinols, 4-hydroxyanisole and mixtures thereof, and (b) adding a working amount of sclareolide to said composition.

Abstract: Composition based on a polyol of formula HO—CH2-CHOH-CH2-OH and on alkyl polyrhamnosides of formula HO—CH2-CHOH-CH2-O-(Rham)x-H; process for preparing same, and cosmetic or pharmaceutical composition comprising same.

Abstract: Composition based on fatty alcohols and on alkyl polyrhamnosides; process for the preparation thereof; cosmetic or pharmaceutical composition comprising same; and use thereof as an emulsifier.

Abstract: Suggested is a mixture comprising or consisting of: (a) a protein extract obtained from cereal gluten extracted by means of aqueous ethanol, said extract being characterized by a content of at least 50 wt.-% proteins having a molecular weight of at least 22 kDa; (b) at least one organic acid; and (c) at least one cosmetically acceptable carrier.

Abstract: The present invention relates to a process for treating hair wherein hair is applied two compositions one after another with an optional rinse off step in order to increase effectiveness of the active compounds comprised in only in the first composition applied onto hair.

Abstract: Various embodiments provide topical compositions and methods for treating the skin to modulate the skin microbiome. The application of various embodiments of the topical composition may modulate the growth of various commensal bacterial in the skin microbiome when applied to the skin, which may improve the immune function of the skin and/or reduce premature aging of the skin.

Abstract: The notification concerns a styling composition for temporary shaping of keratinous fibers comprising a) at least one modified starch, preferably a dextrin, b) at least one natural plant exudate and/or extract, and c) at least one guar derivative.

Abstract: The present invention provides an epilatory composition comprising an admixture of a hydrocarbon resin material and a mineral oil in weight ratio of 1.3:1 to 2.8:1, particulate silica, and, a polyethylene in the form of a homopolymer. An advantage of the compositions of the present invention is that they are able to provide good ‘grip’ to the hair to be removed and so provide for effective hair removal properties.

Abstract: A personal care composition comprises a personal care adjunct ingredient, an anti-dandruff agent, and cationic co-polymer disposed on an outer surface of the anti-dandruff agent. The cationic co-polymer has a viscosity of at least 0.09 poise and comprises monomers selected from the group consisting of acrylamide (“AAM”), dimethyl acrylamide (“DMAA”), acrylamidopropyl trimethylamonium chloride (“APTAC”), methacrylamidopropyl trimethylammonium chloride (“MAPTAC”), and combinations thereof.

Abstract: A sulphate free cleansing composition for hair, scalp or skin comprising, in an aqueous continuous phase: a total amount of anionic surfactant, amphoteric surfactant and zwitterionic surfactant consisting of: (i) from 3 wt % to 13 wt %, by weight of the total composition at 100% activity, of an alpha olefin sulfonate anionic surfactant of general formula (I): R1—CH?CH—CH2—SO3-M+ (I) in which R1 is selected from linear or branched alkyl groups having from 11 to 13 carbon atoms and mixtures thereof; and M is a solubilizing cation; (ii) from 1 to 6%, by weight of an amphoteric or zwitterionic surfactant, selected from an alkyl betaine of general formula (II) R2—N+(CH3)2—CH2—COO-M+ (II) wherein R2=C12 (Lauryl) or Coco derived; an alkyl hydroxy sultaine of general formula (III), R3—N+(CH3)2—CH2—CH(0H)—CH2—S03-M+ (III) wherein R3=C12 (Lauryl) or Coco derived; an alkyl aminopropyl hydroxy sultaine of general formula (IV), R4—C0-NH—(CH2)3—N+(CH3)2—CH2—CH(0H)—CH2—S03-M+ (IV) wherein R4=C12 (Lauryl) or Coco derived; an

Abstract: The present disclosure is related to a method of treating and concealing a skin defect in a subject. The method comprises applying a makeup composition to the skin defect, wherein the makeup composition comprises silicone and a coloring agent, wherein the makeup composition simultaneously conceals and treats said skin defect. Makeup compositions and kits for treating and concealing skin defects are also disclosed.

Abstract: This document provides methods and materials related to hair care. For example, hair care compositions containing one or more quaternized polysiloxanes, one or more zwitterionic surfactants, one or more anionic surfactants, one or more botanical compounds, one or more amino acids, one or more vitamins, or any combination thereof as well as methods for using such hair care compositions are provided.

Abstract: The present invention is directed to a leave-on hair care composition and a hair treatment agent employing the leave-on hair care composition, mainly for curly hair. The leave-on hair composition comprises high concentrations of cationic polymer associated with a fatty alcohol, vegetal oil and at least two cationic surfactants, its uses and method for controlling the frizz.

Abstract: Toothpaste formulations supporting the health, well-being, and/or appearance of a user's skin is described herein, as are coordinated uses of such formulations. Methods of using these formulations to support the beauty, health, well-being, and/or appearance of a user's skin are described. Kits are also identified.

Abstract: Compositions and methods to avoid the gag reflex to enable swallowing of pills, by applying an edible coating to the pill that generates bubbles, so that the bubbles prevent direct contact of the pill with the back of the mouth, thereby avoiding the gag reflex. Preferably the coating generates bubbles from an acid-base reaction, from compressed bubbles entrapped in hard candy, or from any other manner for creating fizzing, effervescent or popping confectionary or other food products. Optionally the coating can have a strong taste, such as by being sour, to distract away from the gag reflex. Optionally, a time release envelope is provided to delay bubbling or to block atmospheric humidity.

Abstract: The present invention is a novel method using a MegaRibavirin aerosol or a MegaRibavirin combination of therapeutics for the treatment of viral disease particularly the pandemic influenza strains “swine” 2009 HI N1 and H5N1. This invention utilizes Ribavirin in an aerosol Mega Dose (61-161 mg/ml) alone or combined with or without other antivirals, a perfluorocarbon emulsion and anti-inflammatory/anti-oxidants. Where applicable, the perfluorocarbon emulsion may dissolve these agents enabling a depot effect and possible protracted delivery. In addition, perfluorocarbon emulsions have the possible added benefit of oxygen carrying capacity and alveolar nitric oxide sequestration, which may reduce peroxynitrite formation and decrease Influenza severity.

Abstract: Disclosed are methods useful for the topical therapeutic treatment of skin malignancies including skin cancers and cutaneous metastases using compositions containing nanoparticles of paclitaxel or other taxanes.

Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Abstract: The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising a therapeutic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: Methods are provided to prevent and to treat urogenital (e.g., urovaginal) atrophy syndrome of menopause by using a vasodilator such as an angiotensin receptor blocker, ACE inhibitor, or calcium channel blocker. More particularly, the methods do not employ orally administered vasodilators, but instead vasodilators that are administered through contact with the epidermis, e.g., in topical or other form suitable for contact with tissues to be treated.

Abstract: Self-emulsifying drug delivery systems are provided for oral delivery of cannabinoids. The cannabinoids are dissolved in an oily medium (e.g. medium chain triglycerides) together with at least one surfactant to improve dissolution, stability, and bioavailability. Also provided are methods comprising uses of an oral cannabinoid compositions for the treatment of neuropathic pain in a subject.

Abstract: The present invention is directed to a palatable soft-chew veterinary composition comprising at least one active agent, at least one wetting agent, and at least one palatant or flavorant. The present invention also provides methods for controlling or treating a condition in an animal comprising administering the palatable composition to an animal in need thereof.

Abstract: An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provide. The composition contains, at a minimum, (a) at least one GHB drug in a first pulse release which releases in less than about 3 hours; (b) at least one GHB drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent; and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one GHB drug in the stomach for at least about 3 hours.

Abstract: The present invention comprises methods and formulations to increase drug payload, especially in regard to a receptacle-based, inhalation dosed, dry powder therapeutic, wherein the methods and formulations are characterized by a high product density, as well as a high TLD per receptacle, while maintaining highly efficient aerosol performance from the device. Embodiments of the present invention comprise a spray-dried pharmaceutical powder comprising particles deliverable from a dry powder inhaler, the composition comprising active agent, and a shell-forming excipient, wherein the powder is characterized by a product density greater than 50 mg/ml.

Abstract: Provided herein is an oral liquid suspension that includes topiramate, as well as methods of medical treatment that include orally administering the oral liquid suspension.

Abstract: Methods are provided to prevent and to treat pressure ulcers (e.g., caused by ischemia) by using a vasodilator such as an angiotensin receptor blocker, ACE inhibitor, or calcium channel blocker. More particularly, the methods do not employ orally administered vasodilators, but instead vasodilators that are administered through contact with the epidermis, e.g., in topical or other form suitable for contact with tissues to be treated.

Abstract: The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.

Abstract: An object of the present invention is to provide a non-aqueous composition having a drug carried therein, the composition being capable of preparing a drug-containing fat emulsion that is usable as an injection, an eye drop, a nasal drop, an inhalant, or the like by being mixed with an aqueous medium in use without producing a drug-containing fat emulsion in advance, and a method for producing the non-aqueous composition. The non-aqueous composition having a drug carried therein of the present invention as a resolution for achieving the object is characterized by comprising an oil or fat, a slightly water soluble drug, and an emulsifier which are dissolved in a polyhydric alcohol as a water soluble carrier at a content of the oil or fat of 0.05 to 250 mg/g, a weight ratio of the slightly water soluble drug to the oil or fat (slightly water soluble drug/(oil or fat)) of 0.

Abstract: A compound includes an amphiphilic polymer with a hydrophobic block including monomeric units chosen from alkyl (meth)acrylates, alkyl (meth)acrylamides, and combinations thereof; and a hydrophilic cationic block including monomeric units chosen from alkylamino (meth)acrylates, alkylamino (meth)acrylamides, and combinations thereof. The polymer is in the form of a micelle with a central core derived from the hydrophobic block and shell at least partially surrounding the core. The shell includes a plurality of filamentous arms derived from the hydrophilic block and emanating outward from the core. A biological agent is associated with the arms of the micelle.

Abstract: Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.

Abstract: Embodiments disclosed herein relate to a package comprising a plurality of chambers, each of the plurality of chambers comprising a solid unit dosage comprising an active ingredient, wherein the package is configured to provide an individualized delivery of the active ingredient in different concentrations of the active ingredient to a human or an animal. The effective amount of active ingredient is adjusted in the solid unit dosage according to the size or weight of solid unit dosage. The manufacture of the solid unit dosage comprises mixing of the active substance with pharmaceutically acceptable additives, followed by hot or cold extrusion and spheronization. The solid unit dosages can be manufactured without the use of a tablet press, lyophilization or molding. Solid unit dosages with various drug loads or many drug strengths simultaneously are produced in one batch without further processing.

Abstract: A method for preparing granules a slurry containing solid API powder particles dispersed in a liquid is prepared. The slurry is fed to a granulator and mixed with a dry base powder within the granulator in order to produce a slurry/base powder mixture. The slurry/base powder mixture produced within the granulator is dried in order to obtain granules containing the solid API particles and the base powder.

Abstract: The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.

Abstract: The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioactive agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.

Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.

Abstract: The present invention relates to the use of a copolymer having the following formula (II): wherein: A1 is a linker, preferably an enzyme cleavable peptide sequence, and y is 0 or 1; AA is a residue of a hydrophobic amino acid; x is an integer comprised between 17 and 270; n is an integer comprised between 5 and 170; and m is an integer comprised between 0 and 80; optionally in the presence of a co-surfactant, as surfactant for the stabilization of an emulsion at a pH between 4 and 6.5.

Abstract: A targeting nanoparticle composition and method of treatment for diseases associated with major basement membrane components of blood vessels accessible from blood stream is presented. The composition includes pegylated perfluorocarbon nanoparticles having a targeting ligand attached that targets the basement membrane components, specifically collagen IV. The targeted nanoparticles may contain at least one pharmaceutically active agent capable of treating a glomerular disease such as lupus nephritis.

Abstract: A composite nanoparticle, a preparation method thereof and preparation method of a composite nano preparation using thereof, wherein the composite nanoparticle is a polymer-lipid nanoparticle encapsulating psoralen, isopsoralen and paclitaxel simultaneously, and the preparation method thereof comprises the following steps of: S1. dissolving soybean lecithin and DSPE-PEG2000 in an aqueous phase, subjected to blending and preheating; and S2. dissolving psoralen, isopsoralen, paclitaxel and PLGA in an oleic phase, subjected to blending and injecting into the aqueous phase of S1 to obtain a mixture, and then heating and blending the mixture to obtain the composite nanoparticle.

Abstract: The invention relates to solid lipid nanoparticle for intracellular release of active substances, can be used in the pharmaceutical industry, in the medicine, cosmetics, as well as for food supplements. Solid lipid nanoparticle has spherical shape with a diameter of 15-100 nm, the lipid is a solid lipid selected from natural plant wax or its synthetic analogue, as the surface acting agent is used TMDSC. The particles of solid lipid nanoparticle is characterized with high melting point, high lipophilicity and low (or lack) of in-vitro dissolution profile. The system is lipase-resistant and is capable to freely penetrate through cell membranes into cells where to release the active substance(s) due to an intracellular digestion with controllable depo-effect. In a second aspect, the invention relates to a method of production of the solid lipid nanoparticle. The preferred technology for production of the compositions is a Phase Inversion Temperature method.

Abstract: The present disclosure relates to oromucosal nanofiber carriers that are mucoadhesive or comprise a mucoadhesive agent for administration of active agents, including substances for their preparation, methods of preparation, and methods of use.

Abstract: Provided are a pharmaceutical composition including geraniol or a pharmaceutically acceptable salt thereof as an active ingredient for use in preventing or treating diabetes mellitus, and a method of preventing or treating diabetes mellitus or a complication due to diabetes mellitus of an individual, in which the method includes administering to the individual a pharmaceutical composition comprising geraniol or a pharmaceutically acceptable salt thereof as an active ingredient and inducing an olfactory stimulation to the individual using the pharmaceutical composition. Also provided is a screening method for an antidiabetic agent that may include contacting a cell expressing an olfactory receptor with a test material; measuring a level of expression of glucagon-like peptide-1 (GLP-1) secreted from the cell; and determining that the test material, when the test material promotes expression of GLP-1, as a candidate material for an antidiabetic agent.

Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.

Abstract: Liquid formulations or syrup comprise an over-the-counter API ingredient or a dietary supplement ingredient. The ingredients are present in concentrated amounts. Multiple doses of the syrups may be packaged in relatively small bottles, such as bottles with a capacity of 100 ml or less.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.